AstraZeneca(AZN) Stock Price Today | Quotes & News - Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

73.050
-1.040-1.40%

Close Mar 25 16:00 ET

72.400
-0.650-0.89%

Pre 05:07 ET

226.48BMarket Cap32.47P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
TipRanks12minutes ago · Ratings
Reported Earlier, AstraZeneca's TAGRISSO Data From LAURA, SAVANNAH, And ORCHARD Trials Highlight Continued Survival Gains And Expanded Role in EGFR+ Lung Cancer
Benzinga03:26 ET
Unusual Options Activity: AZN, FOUR and Others Attract Market Bets, AZN V/OI Ratio Reaches 272.7
Moomoo News16:30 ET
AstraZeneca Call Volume Above Normal and Directionally Bullish
TipRanks15:48 ET
AstraZeneca Announces Results Presented at ELCC on Tagrisso
TipRanks15:01 ET
AstraZeneca (AZN.US) has launched Fanzhuozhuo in China for the maintenance treatment of severe eosinophilic asthma.
AstraZeneca (AZN.US) has launched Fasenra in China for the maintenance treatment of severe eosinophilic asthma (SEA).
Zhitong FinanceMar 25 02:37 ET

Comments

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

$AstraZeneca (AZN.US)$
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

2

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

$Sophia Genetics (SOPH.US)$ $AstraZeneca (AZN.US)$
Global Healthcare Revolution: Elite Hospitals Rush to Implement This Game-Changing Cancer Test

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

Read more

Market Insights

Symbol Mini Chart % Chg

Intchains Group

Hive Blockchain

Unlock the Full List

Investment Theme

Infectious Disease

Infectious Disease